SEC Filing Summary: Spherix Incorporated (Form 8-K)
Business Context and Reporting Period
Company: Spherix Incorporated (Note: Request metadata listed "Dominari Holdings Inc.", but the filing text identifies the registrant as Spherix Incorporated).
Date of Report: July 3, 2017 (Reporting event date: June 30, 2017).
Event: Entry into a Material Definitive Agreement involving the acquisition of equity in a biopharmaceutical development company.
Key Financial Metrics and Transaction Details
- Investment Amount: $675,000.
- Asset Acquired: 6,800,000 shares of common stock of Hoth Therapeutics, Inc. ("Hoth").
- Target Company Profile: Hoth is a development-stage biopharmaceutical company focused on targeted therapeutics for atopic dermatitis (eczema). Its primary asset is an exclusive sublicense from Chelexa Biosciences, Inc. for BioLexa products.
- Ownership Stake: Post-transaction, Hoth had 17,000,000 shares issued and outstanding, giving Spherix approximately a 40% stake.
- Financial Statements: This filing does not provide Spherix's consolidated revenue, profit, cash flow, or debt metrics. It reports a specific capital expenditure/investment event.
Material Changes and Agreements
The filing details three primary agreements executed on June 30, 2017:
- Securities Purchase Agreement: Spherix purchased the shares for $675,000. Hoth covenants to file required Exchange Act reports and seek listing on a trading market (e.g., NYSE, Nasdaq, OTC) following a "Going Public Event" (IPO or merger).
- Registration Rights Agreement: Hoth must register the shares for resale on Form S-1 by June 30, 2018, and use best efforts to have the statement declared effective by December 30, 2018. Spherix receives indemnification against losses related to untrue statements in registration documents and piggyback registration rights.
- Shareholders Agreement:
- Board Representation: Spherix has the right to appoint one director to Hoth's board as long as it holds at least 10% of Hoth's stock.
- Drag-Along Rights: Majority shareholders can force Spherix to sell its shares in a third-party transaction on the same terms.
- Tag-Along and Pre-emptive Rights: Spherix has rights to participate in sales by majority shareholders and to purchase additional equity to maintain its percentage ownership.
- Right of First Refusal: Hoth has the right of first refusal if Spherix receives an offer to sell its shares.
Guidance, Outlook, and Risks
Outlook: The transaction positions Spherix as a significant shareholder in a development-stage biotech firm with a specific focus on eczema treatments. The success of this investment is contingent on Hoth's ability to achieve a "Going Public Event" and successfully develop its licensed therapeutics.
Risks and Contingencies:
- Development Risk: Hoth is a development-stage company; its primary asset is a sublicense, implying reliance on third-party intellectual property and clinical success.
- Liquidity Risk: The shares are subject to resale restrictions until a registration statement is effective or Rule 144 conditions are met.
- Control Risk: Spherix is subject to drag-along rights, meaning it may be forced to sell its investment if a majority of Hoth's shareholders decide to exit.
Investor Verification Checklist
- Verify the current clinical status and regulatory pathway of Hoth's BioLexa products for eczema.
- Confirm Hoth's progress toward a "Going Public Event" (IPO or merger) to satisfy listing covenants.
- Review the financial health of Hoth Therapeutics, Inc., as Spherix's investment value is tied to Hoth's performance.
- Examine the full text of the Shareholders Agreement (Exhibit 10.3) for specific voting thresholds and exit scenarios.
- Check for any subsequent filings regarding the effectiveness of the Form S-1 registration statement required by June 30, 2018.